Richard Aplenc Selected Research

Tics (Tic)

1/2023

Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard Aplenc Research Topics

Disease

68	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2024 - 01/2004
35	Neoplasms (Cancer) 04/2024 - 07/2003
35	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 04/2024 - 08/2002
27	Leukemia 01/2024 - 06/2005
7	Cytokine Release Syndrome 01/2022 - 04/2013
7	Neutropenia 01/2022 - 05/2013
6	Sepsis (Septicemia) 01/2023 - 08/2005
6	Breast Neoplasms (Breast Cancer) 06/2020 - 08/2005
5	Hematologic Neoplasms (Hematological Malignancy) 01/2023 - 05/2014
5	Cardiotoxicity 01/2023 - 10/2009
5	Infections 11/2016 - 04/2007
4	Residual Neoplasm 02/2024 - 01/2020
4	Left Ventricular Dysfunction 01/2023 - 12/2010
4	Fever (Fevers) 01/2022 - 11/2009
4	Neuroblastoma 01/2021 - 06/2014
4	Acute Lung Injury 05/2011 - 07/2007
3	Down Syndrome (Down's Syndrome) 01/2023 - 11/2016
3	Cardiomyopathies (Cardiomyopathy) 01/2022 - 01/2019
3	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021 - 04/2007
3	Myeloid Leukemia (Leukemia, Myelocytic) 07/2017 - 03/2013
3	Wounds and Injuries (Trauma) 05/2011 - 10/2008
2	Septic Shock (Toxic Shock Syndrome) 11/2023 - 06/2013
2	Hodgkin Disease (Hodgkin's Disease) 01/2023 - 01/2022
2	Multiple Myeloma 01/2023 - 01/2018
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2023 - 01/2018
2	Osteosarcoma (Osteogenic Sarcoma) 01/2023 - 01/2022
2	Hyperbilirubinemia 01/2022 - 08/2005
2	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2022 - 11/2014
2	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2022 - 06/2013
2	Second Primary Neoplasms (Neoplasms, Second) 01/2022 - 06/2005
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2021 - 04/2013
2	Critical Illness (Critically Ill) 10/2020 - 01/2016
2	Peripheral Nervous System Diseases (PNS Diseases) 01/2020 - 07/2003
2	Primary Graft Dysfunction 02/2015 - 03/2014
2	Clostridium Infections 12/2014 - 05/2013
2	Body Weight (Weight, Body) 10/2014 - 04/2013
1	Trisomy (Trisomies) 01/2023
1	Tics (Tic) 01/2023
1	Monosomy 01/2023

Drug/Important Bio-Agent (IBA)

13	Gemtuzumab (Mylotarg)FDA Link 01/2024 - 08/2005
11	Chimeric Antigen ReceptorsIBA 04/2024 - 04/2013
9	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 11/2009
7	tisagenlecleucelIBA 02/2024 - 04/2013
6	AnthracyclinesIBA 01/2023 - 08/2005
6	Dexrazoxane (Zinecard)FDA LinkGeneric 01/2023 - 04/2013
5	Bortezomib (Velcade)FDA Link 04/2024 - 01/2017
5	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2023 - 01/2020
5	CytokinesIBA 10/2020 - 04/2007
4	EnzymesIBA 05/2012 - 08/2005
3	Neoplasm Antigens (Tumor Antigens)IBA 04/2024 - 01/2021
3	AntigensIBA 04/2024 - 05/2005
3	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2016
3	nuclear pore complex protein 98IBA 01/2023 - 12/2020
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2017
3	Membrane Proteins (Integral Membrane Proteins)IBA 11/2021 - 01/2014
3	tocilizumab (atlizumab)FDA Link 10/2021 - 04/2013
3	Oxidants (Oxidizing Agents)IBA 02/2015 - 07/2007
3	Cytochrome P-450 CYP3AIBA 08/2005 - 07/2003
2	Proteasome InhibitorsIBA 04/2024 - 01/2014
2	CalicheamicinsIBA 01/2024 - 04/2016
2	insulin receptor-related receptor (IRR)IBA 01/2023 - 05/2013
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2023 - 01/2022
2	Transaminases (Aminotransferases)IBA 01/2022 - 08/2005
2	ProteomeIBA 01/2022 - 01/2021
2	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2020
2	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 05/2016
2	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2021 - 01/2004
2	MicroRNAs (MicroRNA)IBA 01/2020 - 12/2017
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2020 - 05/2013
2	Monoclonal AntibodiesIBA 01/2018 - 01/2014
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2018 - 08/2002
2	Immunoconjugates (Immunoconjugate)IBA 08/2017 - 09/2014
2	Prostaglandins DIBA 02/2015 - 03/2014
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2014 - 01/2010
2	Phosphotransferases (Kinase)IBA 01/2014 - 12/2009
2	Dasatinib (BMS 354825)FDA Link 03/2011 - 12/2009
2	Imatinib Mesylate (Gleevec)FDA Link 03/2011 - 12/2009
2	Estrogen ReceptorsIBA 01/2010 - 05/2009
2	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 01/2010 - 10/2004
2	Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA 06/2005 - 03/2005
1	ChromatinIBA 04/2024
1	Uric Acid (Urate)IBA 01/2024
1	Interleukin-10 (Interleukin 10)IBA 03/2023
1	Long Noncoding RNAIBA 01/2023
1	A 17 (A-17)IBA 01/2022

Therapy/Procedure

47	Therapeutics 04/2024 - 08/2002
44	Drug Therapy (Chemotherapy) 04/2024 - 08/2005
4	Induction Chemotherapy 12/2021 - 03/2013
4	Cell Transplantation 01/2021 - 11/2017
4	Transplantation 01/2021 - 09/2008
4	Immunotherapy 01/2021 - 01/2014
4	Critical Care (Surgical Intensive Care) 01/2018 - 02/2014
3	Length of Stay 01/2019 - 10/2014
3	Adjuvant Chemotherapy 01/2010 - 08/2005
2	Hematopoietic Stem Cell Transplantation 01/2022 - 01/2021
2	Stem Cell Transplantation 01/2022 - 01/2008
2	Bone Marrow Transplantation (Transplantation, Bone Marrow) 05/2014 - 09/2008
1	Secondary Prevention 02/2024
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2023
1	Catheters 01/2023